Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
It’s official: “pipeline in a product” is a thing
Big pharma pipelines are getting smaller, but novel medicines are being tested in more indications than ever before, a new analysis finds.
US pursues pooled testing for Covid-19, and Quest benefits
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
Alzheimer’s catalysts round off a year dominated by Biogen
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Roche pits its targeted cancer Blueprint against Lilly
Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.
Tecentriq’s ovarian failure highlights a changing market
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
Roche and Lilly most vested in research
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
